Stereochemistry | ABSOLUTE |
Molecular Formula | C38H41N5O9 |
Molecular Weight | 711.7602 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(C)C2=CC3=C(C=C)C(C)=C(N3)C=C4N=C([C@@H](CCC(O)=O)[C@@H]4C)C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C5NC(=CC1=N2)C(C)=C5C(O)=O
InChI
InChIKey=VSEIDZLLWQQJGK-WSUYNKMOSA-N
InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1
Molecular Formula | C38H39N5O9 |
Molecular Weight | 709.7444 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). Talaporfin is injected into tumors and other regret tissues where it accumulates. It’s activated with light emitting diodes (LED). It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and glioma and marketed as Laserphyrin. Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
single intravenous injection of talaporfin sodium (40 mg/m(2)) was administered 1 day before resection of the neoplasm
Route of Administration:
Intravenous